May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Ranibizumab for the Treatment of Branch Retinal Vein Occlusion-Associated Cystoid Macular Edema
Author Affiliations & Notes
  • V. D. Alfaro, III
    Retina Consultants of Charleston, Charleston, South Carolina
  • E. P. Jablon
    Retina Consultants of Charleston, Charleston, South Carolina
  • J. B. Kerrison
    Retina Consultants of Charleston, Charleston, South Carolina
  • M. Rodriguez-Fontal
    Retina Consultants of Charleston, Charleston, South Carolina
  • F. Gomez-Ulla
    Retina Consultants of Charleston, Charleston, South Carolina
  • R. Bueno
    Retina Consultants of Charleston, Charleston, South Carolina
  • Footnotes
    Commercial Relationships  V.D. Alfaro, None; E.P. Jablon, None; J.B. Kerrison, None; M. Rodriguez-Fontal, None; F. Gomez-Ulla, None; R. Bueno, None.
  • Footnotes
    Support  Study supported by Genentech, Inc.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2699. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      V. D. Alfaro, III, E. P. Jablon, J. B. Kerrison, M. Rodriguez-Fontal, F. Gomez-Ulla, R. Bueno; Ranibizumab for the Treatment of Branch Retinal Vein Occlusion-Associated Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2699. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Ranibizumab (Lucentis®) is a humanized antigen-binding antibody fragment (Fab) that binds and inhibits all vascular endothelial growth factor-A isoforms and their biologically active degradation products. This study evaluates the safety and efficacy of monthly intravitreal injections of ranibizumab in patients with cystoid macular edema (CME) associated with branch retinal vein occlusion (BRVO).

Methods: : This is a single-center, open-label, 12-month study where patients receive 3 monthly intravitreal injections of either 0.3 mg or 0.5 mg ranibizumab. Eleven patients (out of 20 patients expected) are currently enrolled in this study. Re-treatment with ranibizumab is at the physician’s discretion after the initial 3 injections. The primary efficacy endpoint is the percentage of patients who gained ≥15 letters of best-corrected ETDRS visual acuity (BCVA) at a starting distance of 2 or 4 meters from baseline to 12 months. The secondary endpoints include the change in BCVA from baseline and the change in retinal thickness at each assessment visit as measured by optical coherence tomography and fundus photography, and the incidence and severity of adverse events.

Results: : The first 11 patients received a mean of 7 intravitreal injections (9 patients have completed 12 months and 2 have completed 10 months of the study). After 6 months, ranibizumab treatment resulted in stable vision (a loss of <15 letters) in 100% (11/11) of patients. Mean gain in BCVA at a starting distance of 2 meters was 15.5 ± 14.7 letters compared with baseline, and 55% (6/11) of patients gained ≥15 letters. Central retinal thickness decreased by a mean of 164.4 ± 167.3 µm compared with baseline. The 6-month results were sustained through 12 months (9/11 patients have completed 12 months), with a mean gain in BCVA of 16.2 ± 11.4 letters and a mean decrease in central retinal thickness of 167.9 ± 244.7 µm compared with baseline. Thus far, no serious ocular or systemic adverse events have been reported.

Conclusions: : Ranibizumab is generally well tolerated and may stabilize or improve vision and decrease central retinal thickness in patients with BRVO-associated CME.

Keywords: vascular occlusion/vascular occlusive disease • edema 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×